BioMAP Systems are unique physiologically relevant models of human disease states, superior to human cell lines and simple cell-based assays in yielding physiologically pertinent information on pharmacologic agents.
BioMAP Systems employ low-passage human primary cells which retain native signaling patterns. BioMAP Systems are validated, robust, reproducible, and automated for high throughput.
BioMAP Systems cover disease-specific biology relevant to a variety of indications, including: auto- immune disease, asthma, allergy, cardiovascular disease, COPD, skin inflammation, psoriasis, arthritis and fibrosis, among others.
Different BioMAP Systems include specific combinations of human cells, including the following, among others: endothelial cells, peripheral blood leukocytes, B cells, T cells, macrophages, Th2-type T cells, bronchial and renal epithelial cells, smooth muscle cells, fibroblasts, keratinocytes, M2 macrophages, and myofibroblasts, among others. Since many of the same human cell types are involved in the different disease states, and because in each BioMAP System we simultaneously activate multiple disease-relevant signaling pathways, BioMAP has the unique ability to cross multiple therapeutic areas. For example, virtually all oncology compounds elicit distinct biological activity profiles in the BioMAP Systems developed for autoimmune/inflammatory therapeutic area.
We work closely with our clients to select the BioMAP assay systems most applicable to their needs. Currently there are over 30 BioMAP Systems in operation, and many more under development. Our Diversity Plus panel of 12 BioMAP systems
is a convenient set of systems available for compound profiling
. BioMAP systems under development will are expanding our biology coverage to oncology, metabolism and neuroscience, and to tissues and organs important for drug safety, such as liver and kidney. New systems development is available through custom collaborations
BioMAP System Inputs: Primary cells are stimulated with one or more well-described biological factors to simultaneously activate multiple disease-relevant signaling pathways. The selection of biological factors is guided by generally accepted knowledge of the disease biology and understanding of the importance of pathway interactions and feedback control mechanisms to clinical outcomes. The compound to be tested is added to the primed system.
BioMAP System Outputs: After cell priming and incubation with a test compound the response of the system is determined by measuring biomarker readouts, primarily proteins, chosen to optimally cover a disease space of interest, and also those that have previously been used in clinic. This response, called an activity profile, defines the compound for further analysis with the BioMAP Database
and our Predictive Analysis
to view "A BioMAP System in Detail
" slides and here
to view "BioMAP Diversity Plus Profiling